JP2005523313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523313A5 JP2005523313A5 JP2003585659A JP2003585659A JP2005523313A5 JP 2005523313 A5 JP2005523313 A5 JP 2005523313A5 JP 2003585659 A JP2003585659 A JP 2003585659A JP 2003585659 A JP2003585659 A JP 2003585659A JP 2005523313 A5 JP2005523313 A5 JP 2005523313A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- amino
- dimethylamino
- pharmaceutical composition
- acylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 101
- 239000001257 hydrogen Substances 0.000 claims 101
- -1 tetracycline compound Chemical class 0.000 claims 23
- 239000004098 Tetracycline Substances 0.000 claims 21
- 229960002180 tetracycline Drugs 0.000 claims 21
- 235000019364 tetracycline Nutrition 0.000 claims 21
- 229930101283 tetracycline Natural products 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 9
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 8
- 229960003722 doxycycline Drugs 0.000 claims 8
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims 6
- 229960004023 minocycline Drugs 0.000 claims 6
- 150000003522 tetracyclines Chemical class 0.000 claims 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 5
- 201000004700 rosacea Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 230000003115 biocidal effect Effects 0.000 claims 4
- 230000001937 non-anti-biotic effect Effects 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 3
- XCCHQGIGHCRZOS-KBKZQPOHSA-N (4as,5as,6s,12ar)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@@](C)(O)[C@@H](C[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)C3)(O)C3=O)C3=C(O)C2=C1O XCCHQGIGHCRZOS-KBKZQPOHSA-N 0.000 claims 2
- 239000012954 diazonium Substances 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- MWUTTXATIMURBN-VSAOOKSHSA-N (4aS,5aS,6S,12aR)-3,6,10,11-tetrahydroxy-6-methyl-1,12-dioxo-4a,5,5a,12a-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C[C@]1(O)[C@H]2C[C@H]3CC(O)=C(C(N)=O)C(=O)[C@H]3C(=O)C2=C(O)c2c(O)cccc12 MWUTTXATIMURBN-VSAOOKSHSA-N 0.000 claims 1
- NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 claims 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims 1
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims 1
- HISOCSRUFLPKDE-KLXQUTNESA-N cmt-2 Chemical compound C1=CC=C2[C@](O)(C)C3CC4C(N(C)C)C(O)=C(C#N)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O HISOCSRUFLPKDE-KLXQUTNESA-N 0.000 claims 1
- VCROZLOYPNVPSH-DCKQLXEASA-N cmt-5 Chemical compound N1N=C2C3=C(O)C=CC=C3[C@@](C)(O)C3C2=C1[C@]1(O)C(=O)C(C(N)=O)=C(O)CC1C3 VCROZLOYPNVPSH-DCKQLXEASA-N 0.000 claims 1
- BVFDLIAWTKFZQD-JXVDNWKRSA-N cmt-8 Chemical compound O=C1C2=C(O)C=CC=C2C(C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)C[C@@H]1C2O BVFDLIAWTKFZQD-JXVDNWKRSA-N 0.000 claims 1
- 229960002398 demeclocycline Drugs 0.000 claims 1
- 229910052736 halogen Chemical group 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 C[C@@]([C@@](C[C@@](CC(O)=C(C(N)=O)C1=O)[C@@]11O)C2=C1O)c1c(*)c(C)c(*)c(O)c1C2=O Chemical compound C[C@@]([C@@](C[C@@](CC(O)=C(C(N)=O)C1=O)[C@@]11O)C2=C1O)c1c(*)c(C)c(*)c(O)c1C2=O 0.000 description 8
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37314102P | 2002-04-16 | 2002-04-16 | |
| PCT/US2003/011686 WO2003088906A2 (en) | 2002-04-16 | 2003-04-16 | Methods of simultaneously treating ocular rosacea and acne rosacea |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523313A JP2005523313A (ja) | 2005-08-04 |
| JP2005523313A5 true JP2005523313A5 (https=) | 2006-06-08 |
Family
ID=29250974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585659A Pending JP2005523313A (ja) | 2002-04-16 | 2003-04-16 | 目の酒さ及び酒さ性ざ瘡の同時治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7008631B2 (https=) |
| EP (2) | EP1494681A4 (https=) |
| JP (1) | JP2005523313A (https=) |
| KR (1) | KR20050005444A (https=) |
| AU (1) | AU2003230935B2 (https=) |
| CA (1) | CA2476792A1 (https=) |
| NZ (1) | NZ534613A (https=) |
| WO (1) | WO2003088906A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7211267B2 (en) * | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
| EP2311440A1 (en) * | 2001-04-05 | 2011-04-20 | Collagenex Pharmaceuticals, Inc. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
| US8192749B2 (en) * | 2003-04-16 | 2012-06-05 | Galderma Laboratories Inc. | Methods of simultaneously treating ocular rosacea and acne rosacea |
| WO2004091483A2 (en) | 2003-04-07 | 2004-10-28 | Shire Laboratories, Inc. | Once daily formulations of tetracyclines |
| AU2004261143B2 (en) * | 2003-07-25 | 2009-11-05 | Allergan Pharmaceuticals International Limited | A doxycycline metal complex in a solid dosage form |
| AU2005222937B2 (en) * | 2004-03-12 | 2010-06-17 | Collagenex Pharmaceuticals, Inc. | Method for treating aortic stenosis with non-antibacterial tetracycline formulations |
| US20080242642A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7544373B2 (en) | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7541347B2 (en) | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
| US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
| CA2892739A1 (en) | 2006-12-21 | 2008-07-03 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds for treatment of inflammatory skin disorders |
| WO2008079339A2 (en) | 2006-12-21 | 2008-07-03 | Paratek Pharmaceuticals, Inc. | Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections |
| CN101668511A (zh) * | 2007-02-28 | 2010-03-10 | 阿西克斯医疗公司 | 正常化睑板腺分泌的方法和化合物 |
| US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
| WO2008121107A1 (en) * | 2007-04-02 | 2008-10-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20080305186A1 (en) * | 2007-06-11 | 2008-12-11 | Board Of Regents, The University Of Texas System | Method and Composition for the Treatment of Cardiac Hypertrophy |
| WO2010017310A1 (en) | 2008-08-06 | 2010-02-11 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
| US8107283B2 (en) * | 2009-01-12 | 2012-01-31 | Macronix International Co., Ltd. | Method for setting PCRAM devices |
| US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
| US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
| AU2013214693B2 (en) * | 2012-02-02 | 2017-02-23 | Kenneth Gek-Jin OOI | Improvements in tear film stability |
| FR3000396A1 (fr) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | Combinaison de laropiprant et de doxycycline pour le traitement de la rosacee |
| US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
| FR3026010B1 (fr) * | 2014-09-18 | 2016-11-04 | Galderma Sa | Compositions comprenant un compose de la famille des avermectines et de la doxycycline pour le traitement de la rosacee |
| FR3064482B1 (fr) * | 2017-04-03 | 2020-11-13 | Horus Pharma | Composition topique de doxycycline |
| JP7561029B2 (ja) | 2018-01-07 | 2024-10-03 | ドクター レディズ ラボラトリーズ リミテッド | 炎症性皮膚状態を処置するためのミノサイクリン |
| EP3852734A1 (en) * | 2018-09-22 | 2021-07-28 | Novaliq GmbH | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
| CN111499545B (zh) * | 2020-04-27 | 2022-05-03 | 武汉英纳氏药业有限公司 | 一种对氨基取代苯酚类化合物的制备方法 |
| EP4551552A1 (en) * | 2022-07-08 | 2025-05-14 | ICM (Institut du Cerveau et de la Moelle Épinière) | Tetracycline derivatives |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957918A (en) * | 1988-06-09 | 1990-09-18 | Leonard Bloom | Topical treatment of blepharitis |
| US5827840A (en) * | 1996-08-01 | 1998-10-27 | The Research Foundation Of State University Of New York | Promotion of wound healing by chemically-modified tetracyclines |
| US5908838A (en) * | 1998-02-19 | 1999-06-01 | Medics Pharmaceutical Corporation | Method for the treatment of acne |
| US6015803A (en) * | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
| DE69940227D1 (de) | 1998-05-08 | 2009-02-12 | Univ Miami | Verwendung von sub-antimikrobiellen tetracyclinen zur Behandlung von okularer Rosacea |
| US6071541A (en) * | 1998-07-31 | 2000-06-06 | Murad; Howard | Pharmaceutical compositions and methods for managing skin conditions |
| US6432934B1 (en) | 1998-08-06 | 2002-08-13 | Advanced Vision Research | Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease |
| US6384081B2 (en) | 1998-10-09 | 2002-05-07 | Charles L. Berman | Treatment of diseases of the eye characterized by the formation of metalloproteinase |
| US6664287B2 (en) * | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
| US6495158B1 (en) * | 2001-01-19 | 2002-12-17 | Lec Tec Corporation | Acne patch |
| EP1383508B1 (en) * | 2001-04-05 | 2006-06-21 | Collagenex Pharmaceuticals, Inc. | Doxycycline for the treatment of acne |
| US20040092491A1 (en) | 2002-11-09 | 2004-05-13 | The Research Foundation Of State University Of New York | Method of treating sepsis-induced ARDS |
-
2003
- 2003-04-16 EP EP03724047A patent/EP1494681A4/en not_active Ceased
- 2003-04-16 NZ NZ534613A patent/NZ534613A/en not_active IP Right Cessation
- 2003-04-16 AU AU2003230935A patent/AU2003230935B2/en not_active Ceased
- 2003-04-16 JP JP2003585659A patent/JP2005523313A/ja active Pending
- 2003-04-16 EP EP11152602A patent/EP2368557A1/en not_active Withdrawn
- 2003-04-16 KR KR10-2004-7016366A patent/KR20050005444A/ko not_active Ceased
- 2003-04-16 US US10/414,808 patent/US7008631B2/en not_active Expired - Fee Related
- 2003-04-16 WO PCT/US2003/011686 patent/WO2003088906A2/en not_active Ceased
- 2003-04-16 CA CA002476792A patent/CA2476792A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523313A5 (https=) | ||
| JP2005533766A5 (https=) | ||
| CA2485677A1 (en) | Methods of treating allergic reactions | |
| JP2004536046A5 (https=) | ||
| AU2002256092C1 (en) | Controlled delivery of tetracycline compounds and tetracycline derivatives | |
| AU2007208214B2 (en) | Methods of increasing oral bioavailability of tetracyclines | |
| JP5744976B2 (ja) | にきびの治療方法発明の分野 | |
| JP2018184417A5 (https=) | ||
| CA2440472A1 (en) | Methods of treating acne | |
| JP2023109947A5 (https=) | ||
| JP2006508128A5 (https=) | ||
| AU759372B2 (en) | A novel inhibitor of cataract formation | |
| CN110753540A (zh) | 瑞格列净的口服药物制剂 | |
| AU2003226112B9 (en) | Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins | |
| NZ538198A (en) | Method for reducing C-reactive protein (CRP) levels by administering a non-antibacterial tetracycline formulation or a low dose of an antibacterial tetracycline formulation | |
| AU2018303807B2 (en) | Treatment of non-inflammatory lesions | |
| AU2005222937B2 (en) | Method for treating aortic stenosis with non-antibacterial tetracycline formulations | |
| JPWO2021048280A5 (https=) | ||
| Kalvit et al. | 32 Newer Tetracyclines—Eravacycline and Omadacycline | |
| WO2004054509A2 (en) | Tetracyclines as anti-fungal agents for treatment of ringworm | |
| JPWO2023170065A5 (https=) | ||
| JP2007535502A5 (https=) | ||
| JPWO2023144341A5 (https=) | ||
| JPWO2023139147A5 (https=) | ||
| JPWO2021178371A5 (https=) |